这是一项试点概念验证研究，旨在评估定制的 15 基因循环肿瘤 DNA (ctDNA) 组合作为潜在的伴随分子下一代测序 (NGS) 检测的效用，用于识别非肿瘤中的体细胞单核苷酸变异和插入缺失。 -小细胞肺癌（NSCLC）患者。定制面板涵盖 EGFR、KRAS、NRAS、BRAF、PIK3CA、ERBB2、MET、KIT、PDGFRA、ALK、ROS1、RET、NTRK1、NTRK2 和 NTRK3 基因的热点突变，这些基因可作为指导 NSCLC 患者治疗决策的生物标志物。

This is a pilot proof-of-concept study to evaluate the utility of a custom 15-gene circulating tumour DNA (ctDNA) panel as a potential companion molecular next-generation sequencing (NGS) assay for identifying somatic single nucleotide variants and indels in non-small-cell lung cancer (NSCLC) patients. The custom panel covers the hotspot mutations in EGFR, KRAS, NRAS, BRAF, PIK3CA, ERBB2, MET, KIT, PDGFRA, ALK, ROS1, RET, NTRK1, NTRK2 and NTRK3 genes which serve as biomarkers for guiding treatment decisions in NSCLC patients.